Could Tecentriq's Bladder Cancer Setback Be A Class Effect?

12 May 2017

• By Sukaina Virji

The failure earlier this week of Roche's Tecentriq in second line bladder cancer left both the company and analysts surprised. Bladder cancer is a competitive space with a number of other immune-oncology products at or close to market. What does the Tecentriq result mean for them?

Inchworms — Does Roche's failure indicate need for route change for IO in bladder cancer? • Source: Shutterstock

Roche's difficulties in confirming Tecentriq's efficacy in second line bladder cancer will likely have sent a shiver of unease through its competitors, rather than a cheer. (Also see "Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial" - Scrip, 10 May, 2017.)

Tecentriq (atezolizumab) is one of five similar products on or close to market for the same indication. Could this be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

04 Jun 2025

• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

04 Jun 2025

• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

04 Jun 2025

• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.